What Happened?
Charlestown, MA-based SeLux Diagnostics Appointed Steve Lufkin as Chief Executive Officer
About the Company
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.
About the Person
Steve Lufkin is Chief Executive Officer at SeLux Diagnostics. Previously, Steve held various senior HR leadership roles in the industry.
Info Source
News
Short Profile